secwatch.observer — SEC 8-K summary
======================================

Issuer:     KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)
CIK:        0001877184
Form:       8-K
Filed at:   2026-09-14T20:04:29+00:00
Accession:  0001193125-26-390535
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kestra Medical raises FY27 revenue guidance to $141M after Q1 revenue up 60% to $31.0M
--------------------------------------------------------------------------------

- F1Q27 revenue of $31.0M, up 60% YoY; gross margin expanded to 56.5% from 45.7%.
- GAAP net loss widened to $44.1M from $25.8M; adjusted EBITDA loss was $24.0M vs $19.4M.
- FY27 revenue guidance raised to $141M, representing 48% growth compared to FY26.
- Cash and investments totaled $244.7M; total liquidity ~$320M including term-loan availability.
- Growth driven by WCD market expansion, competitive share gains, new sales territories, and higher in-network mix.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1877184/000119312526390535/0001193125-26-390535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1877184/000119312526390535/ck0001877184-20260914.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-390535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer